Pathos AI

Pathos AI is a clinical-stage AI and technology drug development company. From its funding announcement.

$237M Series ERaised 2 days agoNYC, USABiotech & PharmaUSA
Visit website →

In their own words

What Pathos AI says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "clinical-stage AI and technology drug development company". Source

ProductResearch and development

Public signal Read from the company's own description of what the funding supports.

Why now

Where Pathos AI is today

Pathos AI announced a Series E round of $237M on 26 October 2026, led by Bristol Myers Squibb (NYSE: BMY).

Latest round
Series E
Amount
$237M
Announced
26 October 2026
Headquarters
NYC, USA
Sector
Biotech & Pharma
Growth stage
Series C+
Investors
Also participating
existing investors
Relevant leadership
CEO Iker Huerga

Momentum AfterRaise intelligence

AfterRaise Score

81
High momentum
1 funding signal in the last 90 days
Funding recency
40/40
announced within the last 30 days
Round scale
22/25
round size relative to the market
Funding stage
19/20
Series E
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 26 October 2026
    $237M Series E
    Led by Bristol Myers Squibb (NYSE: BMY).

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Product launches and new tiers
  • Product leadership hiring
  • Research programme expansion
  • Scientific team growth

Opportunities this could create

  • Clinical operations
  • Scientific hiring
  • Licensing and BD partnerships
  • Product leadership
  • Design partners

Based on the Biotech & Pharma sector, a Series C+ round and the priorities the company itself set out. Not a statement of fact.

Medium momentum3 connected signals
  • 26 October 2026$237M Series E announced
  • 26 October 2026Stated priority: product
  • 26 October 2026Stated priority: research and development

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Pathos AI is open to

Not yet specified

Pathos AI has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Pathos AI

All opportunities
OpportunityJOBPublic signal5 days ago
Pathos AI
San Francisco

Executive Assistant

Pathos AI is hiring for this role on its own job board, after raising $237M.

Who they want
Approach preferences not yet specified
Apply on Pathos AI’s site →Company page
OpportunityJOBPublic signal3 months ago
Pathos AI
San Francisco

Founding Marketing Lead

Pathos AI is hiring for this role on its own job board, after raising $237M.

Who they want
Approach preferences not yet specified
Apply on Pathos AI’s site →Company page
OpportunityJOBPublic signal11 months ago
Pathos AI
San Francisco

AI Research Engineer

Pathos AI is hiring for this role on its own job board, after raising $237M.

Who they want
Approach preferences not yet specified
Apply on Pathos AI’s site →Company page

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Pathos AI?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector